Since the company is now , it is not possible to buy or sell shares on public markets.
: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook trxc stock buy or sell
: As a result of becoming a private subsidiary of KARL STORZ, the common stock has ceased trading on the NYSE American Exchange. Historical Context (TRXC to ASXC) Since the company is now , it is
: Shareholders at the time of the merger were entitled to receive the $0.35 per share cash payout. Historical Context (TRXC to ASXC) : Shareholders at
The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting
: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery".